Logo image of TCRR

TCR2 THERAPEUTICS INC (TCRR) Stock Fundamental Analysis

NASDAQ:TCRR - Nasdaq - US87808K1060 - Common Stock - Currency: USD

1.48  -0.09 (-5.73%)

After market: 1.53 +0.05 (+3.38%)

Fundamental Rating

2

TCRR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. TCRR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TCRR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TCRR had negative earnings in the past year.
TCRR had a negative operating cash flow in the past year.
In the past 5 years TCRR always reported negative net income.
In the past 5 years TCRR always reported negative operating cash flow.
TCRR Yearly Net Income VS EBIT VS OCF VS FCFTCRR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

The profitability ratios for TCRR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCRR Yearly ROA, ROE, ROICTCRR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

TCRR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRR Yearly Profit, Operating, Gross MarginsTCRR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for TCRR has been increased compared to 1 year ago.
TCRR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCRR Yearly Shares OutstandingTCRR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
TCRR Yearly Total Debt VS Total AssetsTCRR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

TCRR has an Altman-Z score of -6.44. This is a bad value and indicates that TCRR is not financially healthy and even has some risk of bankruptcy.
TCRR's Altman-Z score of -6.44 is on the low side compared to the rest of the industry. TCRR is outperformed by 70.08% of its industry peers.
There is no outstanding debt for TCRR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.44
ROIC/WACCN/A
WACCN/A
TCRR Yearly LT Debt VS Equity VS FCFTCRR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.96 indicates that TCRR has no problem at all paying its short term obligations.
With a Current ratio value of 2.96, TCRR is not doing good in the industry: 69.28% of the companies in the same industry are doing better.
A Quick Ratio of 2.96 indicates that TCRR has no problem at all paying its short term obligations.
With a Quick ratio value of 2.96, TCRR is not doing good in the industry: 68.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
TCRR Yearly Current Assets VS Current LiabilitesTCRR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TCRR have decreased strongly by -49.47% in the last year.
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.12% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRR Yearly Revenue VS EstimatesTCRR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 100M 200M 300M
TCRR Yearly EPS VS EstimatesTCRR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCRR. In the last year negative earnings were reported.
Also next year TCRR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRR Price Earnings VS Forward Price EarningsTCRR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRR Per share dataTCRR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

TCRR's earnings are expected to grow with 17.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.45%
EPS Next 3Y17.13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCRR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TCR2 THERAPEUTICS INC

NASDAQ:TCRR (5/31/2023, 8:00:02 PM)

After market: 1.53 +0.05 (+3.38%)

1.48

-0.09 (-5.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-11 2023-05-11/bmo
Earnings (Next)08-07 2023-08-07/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners9.57%
Ins Owner Change0%
Market Cap58.11M
Analysts73.33
Price Target5.86 (295.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-70.94%
Min EPS beat(2)-93.38%
Max EPS beat(2)-48.5%
EPS beat(4)1
Avg EPS beat(4)-34.1%
Min EPS beat(4)-93.38%
Max EPS beat(4)7.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.37%
PT rev (3m)-41.98%
EPS NQ rev (1m)-34.75%
EPS NQ rev (3m)0.13%
EPS NY rev (1m)0%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-4.2
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-3.16
FCFYN/A
OCF(TTM)-2.81
OCFYN/A
SpS0
BVpS2.58
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 461.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -6.44
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)454.2%
Cap/Depr(5y)411.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-81.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.19%
OCF growth 3YN/A
OCF growth 5YN/A